| P2093 | author name string | Crooke ST | |
| P2860 | cites work | Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII | Q22004015 |
| | Molecular cloning and expression of cDNA for human RNase H. | Q32086235 |
| | Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer | Q33330493 |
| | Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma | Q33332247 |
| | Properties of cloned and expressed human RNase H1. | Q33874988 |
| | Morpholino antisense oligomers: the case for an RNase H-independent structural type | Q33901587 |
| | Novel mechanisms for antisense-mediated regulation of gene expression | Q33916092 |
| | Antisense oligonucleotides as a tool for gene functionalization and target validation | Q33916097 |
| | Molecular mechanisms of action of antisense drugs | Q33916100 |
| | A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides | Q33916114 |
| | Human Bcl-2 antisense therapy for lymphomas | Q33916124 |
| | 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation | Q33916133 |
| | Antisense properties of peptide nucleic acid | Q33916142 |
| | Conformationally restricted carbohydrate-modified nucleic acids and antisense technology | Q33916146 |
| | The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells | Q33957440 |
| | Therapeutic applications of oligonucleotides | Q35153579 |
| | Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides | Q35230003 |
| | Biologic and therapeutic significance of MYB expression in human melanoma | Q35237618 |
| | Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide | Q35237895 |
| | Site specific enzymatic cleavage of RNA | Q35758603 |
| | Purification and characterization of human ribonuclease HII. | Q35873753 |
| | Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. | Q36437931 |
| | Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice | Q37585661 |
| | Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy | Q38296093 |
| | Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin | Q38300743 |
| | Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets | Q38320249 |
| | Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element | Q38334658 |
| | Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. | Q38342120 |
| | Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation | Q38343811 |
| | The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity | Q38344190 |
| | Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids | Q38349308 |
| | Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. | Q40449252 |
| | Alpha-DNA.IX: Parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. | Q40451200 |
| | Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates | Q40537453 |
| | RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds | Q40539121 |
| | Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro | Q40546194 |
| | Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). | Q40629963 |
| | Antisense oligonucleotides as therapeutic agents--is the bullet really magical? | Q40834751 |
| | Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes | Q41908017 |
| | Implication of RNA structure on antisense oligonucleotide hybridization kinetics | Q45059437 |
| | A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. | Q52871121 |
| | Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide | Q54685574 |
| | BCL-2 antisense therapy in patients with non-Hodgkin lymphoma | Q61868294 |
| | Therapeutic Applications of Oligonucleotides | Q68156172 |
| | Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system | Q71773051 |
| | Evaluating the mechanism of action of antiproliferative antisense drugs | Q73774527 |
| P433 | issue | 56 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 6651-6659 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Potential roles of antisense technology in cancer chemotherapy | |
| P478 | volume | 19 | |